company

Abbott Laboratories

Healthcare / Medical Devices / Diagnostics
78Good
Aio Composite Score
Confidence
ApplicationModerate
medium
ImpactNeutral
medium
OpennessTransparent
medium
Abbott Laboratories is an aggressive adopter of AI in its core medical device and diagnostics products, with documented use cases including AI-powered OCT cardiac imaging software (Ultreon), ML-based heart attack risk prediction, and an acquisition of AI-based cardiac software developer LARALAB. The company has published a five-point Responsible AI framework and established an executive Data Use & Ethics Board, signaling meaningful governance investment. Layoffs reported across 2024–2025 appear tied to business restructuring and declining demand in specific product lines rather than AI-driven displacement, with no evidenced causal link between AI adoption and workforce reductions.
Application
How is AI being used?
Moderate
medium
Abbott deploys AI in production medical device software (Ultreon, LARALAB) and diagnostic algorithms, with clinicians retaining final decision-making…
Impact
How have people been affected?
Neutral
medium
Abbott's AI applications are clinically oriented with stated benefits for diagnostic accuracy and surgical decision support. Layoffs reported in…
Openness
Company honesty about AI use.
Transparent
medium
Abbott has publicly disclosed a Responsible AI framework, an executive ethics board, and specific AI product use cases; the 10-K acknowledges AI as a…
AI Tools & Platforms Detected
Ultreon (AI-powered OCT imaging software)ML algorithm for heart attack risk predictionLARALAB AI cardiac software (acquired)FreeStyle Libre CGM platform (AI/data-driven)
AI Hiringweak
2AI roles/ 343 total
Sr. Staff AI/Machine Learning EngineerSenior AI-Machine Learning EngineerPrincipal AI/ML EngineerPrincipal AI EngineerStaff AI/Machine Learning Engineer
Key Evidence (7)
Abbott's Ultreon software uses AI to auto-detect calcium levels and blood vessel diameters in real time during cardiac procedures using OCT imaging
web searchSource ↗
Abbott developed an ML algorithm to identify individuals at risk of a heart attack
web searchSource ↗
Abbott acquired LARALAB, a German AI-based cardiac software developer, to expand its digital health and cardiovascular technology portfolio
web searchSource ↗
Abbott's executive Data Use & Ethics Board set enterprise AI principles, and Abbott published a five-point Responsible AI framework pledging safety, fairness, and transparency
2025
web searchSource ↗
Abbott's 10-K identifies AI as a disruptive technology that could significantly change the competitive landscape and negatively impact demand for certain Abbott products
2026-02-20
sec filingSource ↗
Abbott is actively hiring for AI/ML roles including Sr. Staff AI/ML Engineer, Principal AI/ML Engineer, Senior Algorithm and Data Science Engineer, and Associate Director of Global Data Science & Analytics across medical devices and diagnostics divisions
2025
job postingSource ↗
What insider reports could clarify
  • How are AI-generated diagnostic outputs reviewed before informing clinical decisions?
  • Have any roles in R&D or data analytics been replaced or eliminated due to AI tooling?
  • How does Abbott validate AI model accuracy across diverse patient populations?
  • What internal AI tools, if any, are used for employee productivity or administrative work?
  • How does the Responsible AI framework apply to third-party AI tools used internally?
Submit a ReportClaim This Profile